TN2011000380A1 - Triazolopyridine derivatives as p38 map kinase inhibitors - Google Patents

Triazolopyridine derivatives as p38 map kinase inhibitors

Info

Publication number
TN2011000380A1
TN2011000380A1 TN2011000380A TN2011000380A TN2011000380A1 TN 2011000380 A1 TN2011000380 A1 TN 2011000380A1 TN 2011000380 A TN2011000380 A TN 2011000380A TN 2011000380 A TN2011000380 A TN 2011000380A TN 2011000380 A1 TN2011000380 A1 TN 2011000380A1
Authority
TN
Tunisia
Prior art keywords
radical
optionally substituted
map kinase
alkyl
independently
Prior art date
Application number
TN2011000380A
Other languages
English (en)
Inventor
Harry Finch
John Montana
Niel Monique Bodil Van
Chi-Kit Woo
Jamie Knight
Bohdan Waszkowycz
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42232647&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000380(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0902651A external-priority patent/GB0902651D0/en
Priority claimed from GB0908069A external-priority patent/GB0908069D0/en
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of TN2011000380A1 publication Critical patent/TN2011000380A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TN2011000380A 2009-02-17 2011-08-03 Triazolopyridine derivatives as p38 map kinase inhibitors TN2011000380A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0902651A GB0902651D0 (en) 2009-02-17 2009-02-17 Pharmaceutical compounds and compositions
GB0908069A GB0908069D0 (en) 2009-05-11 2009-05-11 Pharmaceutical compounds and compositions
PCT/GB2010/050257 WO2010094956A1 (fr) 2009-02-17 2010-02-16 Dérivés de triazolopyridine utilisés comme inhibiteurs de la p38 map kinase

Publications (1)

Publication Number Publication Date
TN2011000380A1 true TN2011000380A1 (en) 2013-03-27

Family

ID=42232647

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000380A TN2011000380A1 (en) 2009-02-17 2011-08-03 Triazolopyridine derivatives as p38 map kinase inhibitors

Country Status (19)

Country Link
US (1) US8557797B2 (fr)
EP (1) EP2398798A1 (fr)
JP (1) JP2012517992A (fr)
KR (1) KR20110116030A (fr)
CN (2) CN103483338A (fr)
AU (1) AU2010215261A1 (fr)
BR (1) BRPI1005327A2 (fr)
CA (1) CA2752693A1 (fr)
CL (1) CL2011001977A1 (fr)
CO (1) CO6420344A2 (fr)
EA (1) EA201190119A1 (fr)
IL (1) IL214658A0 (fr)
MA (1) MA33128B1 (fr)
MX (1) MX2011008496A (fr)
PE (1) PE20120655A1 (fr)
SG (1) SG174134A1 (fr)
TN (1) TN2011000380A1 (fr)
WO (1) WO2010094956A1 (fr)
ZA (1) ZA201105993B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2212291B1 (fr) * 2007-10-24 2014-06-04 Merck Sharp & Dohme Corp. Antagonistes de canaux calciques de type t à base de phényle amide hétérocyclique
GB201009731D0 (en) * 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
EP2736899A1 (fr) 2011-07-26 2014-06-04 Grünenthal GmbH Dérivés de carboxamide et d'urée aromatiques bicycliques substitués en tant que ligands de récepteur de vanilloïde
KR101994381B1 (ko) 2011-12-09 2019-06-28 키에시 파르마슈티시 엣스. 피. 에이. 키나아제 억제제
SG11201402986RA (en) * 2011-12-09 2014-12-30 Chiesi Farma Spa Kinase inhibitors
KR20140103925A (ko) 2011-12-09 2014-08-27 키에시 파르마슈티시 엣스. 피. 에이. 4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도
WO2014015056A2 (fr) 2012-07-17 2014-01-23 Washington University Médicaments anti-mucus et leurs utilisations
KR20160016973A (ko) * 2013-06-06 2016-02-15 키에시 파르마슈티시 엣스. 피. 에이. P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체
CN105377847A (zh) * 2013-06-06 2016-03-02 奇斯药制品公司 激酶抑制剂
EP3004098B1 (fr) 2013-06-06 2017-08-09 Chiesi Farmaceutici S.p.A. Inhibiteurs de kinase
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EA201790806A1 (ru) 2014-11-05 2017-11-30 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
SG10202110259QA (en) 2017-10-05 2021-10-28 Fulcrum Therapeutics Inc Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
WO1997002289A1 (fr) 1995-07-06 1997-01-23 Zeneca Limited Inhibiteurs peptidiques de la fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (fr) 2001-03-16 2002-09-18 Pfizer Products Inc. Dérivés de purine pour le traitement de l'ischémie
DE60214428T2 (de) 2001-12-20 2007-09-20 Bayer Healthcare Ag 1, 4-dihydro-1, 4-diphenylpyridin-derivate
WO2004072072A1 (fr) 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines utilisees comme composes anti-inflammatoires
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
EP1751139B1 (fr) 2004-04-30 2011-07-27 Bayer HealthCare LLC Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
EP1609789A1 (fr) 2004-06-23 2005-12-28 Eli Lilly And Company Derives de ureido-pyrazole et leur utilisation comme inhibiteurs de kinase
SI1761520T1 (sl) 2004-06-23 2008-10-31 Lilly Co Eli Inhibitorji kinaze
GB0418015D0 (en) * 2004-08-12 2004-09-15 Pfizer Ltd New compounds
PL1778686T3 (pl) 2004-08-12 2009-04-30 Pfizer Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38
JP2008509985A (ja) 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー 炎症治療用の新規トリアゾロピリジン化合物
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
EP1984363A1 (fr) 2006-02-09 2008-10-29 Pfizer Limited Composes triazolopyridine
WO2008024746A1 (fr) 2006-08-21 2008-02-28 Array Biopharma, Inc. Dérivés de l'acide phénoxyphénylacétique 4-substitué
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions

Also Published As

Publication number Publication date
CN103483338A (zh) 2014-01-01
EP2398798A1 (fr) 2011-12-28
PE20120655A1 (es) 2012-06-07
CN102395586A (zh) 2012-03-28
JP2012517992A (ja) 2012-08-09
US20120088763A1 (en) 2012-04-12
KR20110116030A (ko) 2011-10-24
IL214658A0 (en) 2011-09-27
CO6420344A2 (es) 2012-04-16
ZA201105993B (en) 2012-10-31
US8557797B2 (en) 2013-10-15
WO2010094956A1 (fr) 2010-08-26
MA33128B1 (fr) 2012-03-01
AU2010215261A1 (en) 2011-09-08
CL2011001977A1 (es) 2011-11-18
EA201190119A1 (ru) 2012-05-30
SG174134A1 (en) 2011-10-28
MX2011008496A (es) 2011-11-18
CA2752693A1 (fr) 2010-08-26
BRPI1005327A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
TN2011000380A1 (en) Triazolopyridine derivatives as p38 map kinase inhibitors
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
MX2009002802A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparacion y su aplicacion en terapeutica.
MY159239A (en) Urea derivatives that are kinase inhibitors, and their therapeutic use
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
EA201791254A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
GEP20156267B (en) 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
GEP20166484B (en) Protein kinase inhibitors
EA201290260A1 (ru) Бензимидазол-имидазольные производные
MX2010003445A (es) Derivados de nicotinamida, su preparacion y su uso terapeutico.
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
EA201100115A1 (ru) Новые производные аденина
RU2009125578A (ru) Новые замещенные диазаспиропиридиноновые производные для применения в лечении мсн-1-опосредованных заболеваний
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
MX2010006202A (es) Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2010000658A (es) Derivados de pirimidina 934.
MX2016006685A (es) Compuestos heterociclicos de n-acilimino.
MX2022000854A (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr.
NO20085317L (no) Imidazoazepinonforbindelser
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
AR057461A1 (es) Derivados de pirazol, proceso de preparacion, composiciones farmaceuticas y usos
TW200602344A (en) Novel pyrrolo(2, 3-b)pyridine derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
CO6321159A2 (es) Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias
AR083861A1 (es) OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN